Rosalind Advisors Inc. Has $14.28 Million Position in Savara Inc. $SVRA

Key Points

• Rosalind Advisors increased its Savara stake by 50.7% to 4,000,000 shares (worth $14.28M), making SVRA about 5.0% of Rosalind's portfolio and its 7th-largest holding.
• Analyst sentiment is generally positive: several firms raised targets (HC Wainwright, UBS) to $10, MarketBeat's consensus target is $8.86, and the average rating is "Moderate Buy."
• Savara is a clinical-stage biotech with lead candidate Molgradex under regulatory review for autoimmune PAP; the stock trades around $5.32 with a $1.08B market cap and a 52-week range of $1.89–$7.01.

Rosalind Advisors Inc. raised its position in shares of Savara Inc. (NASDAQ:SVRA - Free Report) by 50.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,000,000 shares of the company's stock after buying an additional 1,345,056 shares during the quarter. Savara comprises approximately 5.0% of Rosalind Advisors Inc.'s portfolio, making the stock its 7th biggest position. Rosalind Advisors Inc. owned 2.31% of Savara worth $14,280,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of SVRA. VR Adviser LLC increased its stake in shares of Savara by 172.7% in the 2nd quarter. VR Adviser LLC now owns 8,884,263 shares of the company's stock worth $20,256,000 after acquiring an additional 5,626,624 shares in the last quarter. Swedbank AB purchased a new position in Savara during the 3rd quarter valued at about $1,964,000. Affinity Asset Advisors LLC bought a new stake in Savara during the second quarter worth about $1,140,000. UBS Group AG boosted its stake in Savara by 221.2% during the third quarter. UBS Group AG now owns 695,734 shares of the company's stock worth $2,484,000 after acquiring an additional 479,123 shares in the last quarter. Finally, Nantahala Capital Management LLC grew its holdings in Savara by 3.1% in the second quarter. Nantahala Capital Management LLC now owns 8,325,375 shares of the company's stock worth $18,982,000 after purchasing an additional 250,000 shares during the period. Institutional investors own 87.93% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on SVRA. HC Wainwright raised their target price on shares of Savara from $8.00 to $10.00 and gave the company a "buy" rating in a research note on Tuesday, December 23rd. Guggenheim reissued a "buy" rating on shares of Savara in a research report on Tuesday, December 23rd. UBS Group set a $10.00 price target on Savara in a research note on Tuesday, December 23rd. Wall Street Zen upgraded Savara from a "sell" rating to a "hold" rating in a research note on Saturday, November 15th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Savara in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $8.86.

Savara Stock Down 3.8%

Shares of Savara stock opened at $5.32 on Friday. The company has a 50-day simple moving average of $5.68 and a two-hundred day simple moving average of $4.93. The stock has a market capitalization of $1.08 billion, a PE ratio of -10.04 and a beta of 0.31. Savara Inc. has a 52-week low of $1.89 and a 52-week high of $7.01. The company has a debt-to-equity ratio of 0.32, a quick ratio of 7.65 and a current ratio of 7.65.

About Savara

Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.